Bird & Bird's Venture Capital team advises Horizons Ventures on its investment in Owlstone Medical
Written By
Bird & Bird’s London Corporate team acted for global investor, Horizons Ventures, in its participation in Owlstone Medical’s $58M Series D fundraise. The round was led by Horizons Ventures, a Hong-Kong based VC firm which focuses on disruptive and tech-focussed start-ups.
Owlstone Medical, based in Cambridge UK, is the global leader in breath biopsy for applications in early disease detection and precision medicine. Horizons Ventures now takes a seat on Owlstone Medical’s Board and is joined by select existing and new investors from Asia, the Middle East and the United States.
The team was led by Corporate partner, Struan Penwarden who was assisted by Arif Saleem (Senior Associate) and Greg Turton (Associate).
Struan Penwarden, head of Venture Capital at Bird & Bird said: “We are delighted to have assisted Horizon Ventures on this significant investment into Owlstone Medical, having previously acted for them on the Series C round. The Series D round was an international transaction and the financing will accelerate the development of Owlstone Medical’s innovative technology in the MedTech field. This is a prime example of Bird & Bird’s Venture Capital, Tech and Life Science capabilities.”
